Drugs

Sara Riggare can’t finish her PhD because an ethics committee says she needed their approval first.

“I’m just a girl living with type 1 diabetes who got tired of waiting.”

After watching medical records get traded for billions of dollars, a tech entrepreneur says he can help you grab a share of the bounty.

It’s made out of living human cells. Someday they could be yours.

Investors and families are counting on Onno Faber to galvanize research into neglected conditions—like the one threatening his hearing and sight.

Michael Pollan explores the neuroscience of psychedelics in this excerpt from his new book.

Billionaire Jim Mellon bets that a “stock market mania” will be sparked by technologies that make people live past 100.

Halo Cures, a crowdfunding startup, will usher new drugs and devices through the rockiest stage of development.

A new study helps the case for a supplement known as NR, but it’s not yet a slam dunk.

Racing against his own genetic disorder, Onno Faber is giving people with rare diseases the tools to make medicine work for them.

Leave it to the Brits to invent a synthetic alcohol that gets you properly pickled and doesn’t make you feel poisoned.

But can they manufacture it at scale?

Teleported molecules, custom genomes, and other innovations that will deliver on the technology’s biggest promises.

They’re avoiding many of the substances that got earlier generations high. But are they better off?

Pot is being packaged like fine wines and sold with bold claims about physical and psychological benefits. Does science back up the marketing pitch?